63 results about "Β cryptoxanthin" patented technology

The invention provides a liquid diary products containing lutein ester and cryptpxanthin, using the total weight of the liquid diary products as reference, wherein milk >=35%; lutein ester and cryptpxanthin 0.0008%-0.005%; antioxidant 0.001-0.002%; emulsifier 0.01-0.30%. The liquid diary products are prepared by addinglutein ester and cryptpxanthin into the diary and/or water; shearing and stirring up the mixture for 15-30 minutes by a high-speed shearing stirrer and performing homogenization-treatment of the stirred-up mixture. The invention ensures the good stability and taste of the liquiddiary products in shelf life, using a reasonable formula and proper technology.

A pharmaceutical preparation comprising progestin, estrogen and a multivitamin agent. The progestin may be between 0 and 0.50 mg Desogesterel and the estrogen may be between 0 and 0.2 mg Ethinyl Estradiol. The multivitamin agent may be any combination of alpha carotene, beta carotene, biotin, bioflavonoid, calcium, chasteberry fruit, chromium, copper, coenzyme Q10, cryptoxanthin, dong quai root, folic acid, ginkgo biloba, garlic, grape seed extract, green tea extract, hesperedin, iodine, iron, lutein, malic acid, manganese, magnesium, milk thistle, molybdenum, niacin, panthothenic acid, potassium, pyridoxine HCL, quercetin, riboflavin, rutan, selenium, thiamine, vitamin A, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, zinc, zoexanthin and any combination thereof.

Novel lycopene beta-monocyclase genes were identified and used to transform a host cell to produce β-cryptoxanthin. The host cell produces lycopene and is transformed to express the novel lycopene β-monocyclase that converts lycopene into γ-carotene. The host cell is further transformed to express a lycopene hydroxylase that hydroxylates γ-carotene to 3-hydroxy-γ-carotene and a lycopene β-bicyclase that converts 3-hydroxy-γ-carotene to β-cryptoxanthin. The host cell is grown under conditions whereby γ-carotene is produced which is hydroxylated to 3-hydroxy-γ-carotene and which is converted into β-cryptoxanthin.

A marigold plant, a regenerable portion thereof and seed are disclosed whose flower petals, leaves or flower petals and leaves contain one or more of an enhanced neoxanthin plus violaxanthin ratio, an enhanced β-carotene ratio, an enhanced lycopene ratio, an enhanced α-cryptoxanthin ratio, an enhanced phytoene ratio or an enhanced phytofluene ratio relative to that ratio in a non-mutant marigold. A marigold plant, a regenerable portion thereof and seed are also disclosed whose flower petals contain zeaxanthin esters and are substantially free of esters of both neoxanthin and violaxanthin, and wherein zeaxanthin constitutes at least about one-half of the extractable carotenoids when xanthophylls are assayed as alcohols. Also disclosed are methods of preparing such plants, oleoresins and comestible materials that have such carotenoid ratios.

It is intended to provide an osteogenesis promoter having a remarkable effect of positively promoting osteogenesis and thus preventing/treating bone diseases; a preventive/a remedy for bone diseases such as osteoporosis having both of an osteogenesis-promoting effect and a bone resorption-inhibiting effect; and a method of screening an active ingredient for preventing/treating bone diseases by using a compound having both of an osteogenesis-promoting effect and a bone resorption-inhibiting effect as a lead compound. It is confirmed that beta-cryptoxanthin, which occurs in a large amount in peel and sarcocarp of satsuma orange, has an osteogenesis-promoting effect and a therapeutic effect on bone disease. Thus, beta-cryptoxanthin or its composition is used as an osteogenesis promoter, a preventive/a remedy for bone diseases, a functional food or a food material for preventing/treating bone diseases and a feed composition.

The present invention provides an extract containing a β-cryptoxanthin component from a persimmon fruit, a functional food and/or drink supplemented with the extract, and a process for producing the extract. The present invention produces the extract containing a β-cryptoxanthin component from a persimmon fruit by cutting an inexpensive raw material persimmon fruit, especially a persimmon skin, into fine pieces and extracting a β-cryptoxanthin component with an organic solvent such as ethanol. After the β-cryptoxanthin component is extracted with the organic solvent, it is preferred to eliminate the smell of dried persimmon by removing the organic solvent under reduced pressure. According to the present invention, an extract containing a β-cryptoxanthin component that does not raise consumers' anxiety even when added to foods, drinks, and the like can be produced at low cost.

The present invention explains a realistic and effective process for isolating and purifying carotenoids containing higher concentrations of carotenoids such as trans-lutein, trans-zeaxanthin, Cis-lutein, β-carotene and Cryptoxanthin from Marigold flower petals under controlled conditions leaving no traces of any organic hazardous solvents. The process involves ensilaging Marigold flowers, dehydration, solvent extraction, alkali hydrolysis of carotenoid esters with absolute alcohol, crystallization/purification using water, absolute alcohol mixture followed by filtration and drying until the crystals are considerably free from moisture and absolutely free from residual hazardous solvents. These crystals are suitable for nutraceutical and food products as supplements.

The present invention relates to a process for converting lutein and/or lutein esters to (3R)-β-cryptoxanthin and (3R,6′R)-α-cryptoxanthin, suitable for human consumption as dietary supplements, by employing safe and environmentally friendly reagents. (3R)-β-Cryptoxanthin and (3R,6′R)-α-cryptoxanthin are two rare food carotenoids that are not commercially available and the former exhibits vitamin A activity. In the first synthetic step, commercially available lutein and/or lutein esters are transformed into a mixture of dehydration products of lutein (anhydroluteins) in the presence of a catalytic amount of an acid. The resulting anhydroluteins are then converted to (3R)-β-cryptoxanthin (major product) and (3R,6′R)-α-cryptoxanthin (minor product) by heterogeneous catalytic hydrogenation employing transition elements of group VIII (Pt, Pd, Rh supported on alumina or carbon) in a variety of organic solvents under atmospheric pressure of hydrogen and at temperatures ranging from −15° C. to 40° C. Among these catalysts, Pt supported on alumina at 40° C. in ethyl acetate provides the best yield of (3R)-β-cryptoxanthin and (3R,6′R)-α-cryptoxanthin. Several homogeneous catalysts can also promote the regioselective hydrogenation of anhydroluteins to a mixture of (3R)-β-cryptoxanthin and (3R,6′R)-α-cryptoxanthin in low to moderate yields. The catalysts may be transition metal complexes such as palladium acetylacetonate, Rh(Ph₃P)₃Cl (Wilkinson's catalyst), [(C₆H₁₁)₃P[C₈H₁₂][C₅H₅N]Ir⁺PF6⁻ (Crabtree catalyst), or [C₈H₁₂][(MePh₂P)₂]Ir⁺PF6⁻. Among these, Wilkinson catalyst converts anhydroluteins to (3R)-β-cryptoxanthin and (3R,6′R)-α-cryptoxanthin in nearly quantitative yield. A novel feature of this invention is the regioselective hydrogenation of anhydroluteins while the highly conjugated polyene chain of these carotenoids remains intact.

A composition which has high safety and is excellent in the effect of reducing body fat, such as visceral fat, subcutaneous fat and the like, and neutral fat, and a food, a pharmaceutical and a feed comprising the same, are provided.

An oral administration composition having a body fat reducing action and/or a neutral fat reducing action, which is a composition comprising a carotenoid and a sphingolipid or a carotenoid and a flavonoid and/or a derivative thereof, preferably a composition comprising a cryptoxanthin and a sphingolipid or a cryptoxanthin and a flavonoid and/or a derivative thereof, wherein the cryptoxanthin and/or the sphingolipid and/or the flavonoid are derived from a citrus fruit and the citrus fruit is preferably Citrus unshiu.

(3R)-3-Hydroxy-β-ionone and (3S)-3-hydroxy-β-ionone are two important intermediates in the synthesis of carotenoids with β-end group such as lutein, zeaxanthin, β-cryptoxanthin, and their stereoisomers. Among the various stereoisomers of these carotenoids, only (3R,3′R,6′R)-lutein, (3R,3′R)-zeaxanthin, and (3R)-β-cryptoxanthin are present in commonly consumed fruits and vegetables. There are 3 possible stereoisomers for zeaxanthin, these are: dietary (3R,3′R)-zeaxanthin (1), non-dietary (3S,3′S)-zeaxanthin (2), and non-dietary (3R,3′S;meso)-zeaxanthin (3) which is a presumed metabolite of dietary lutein. Dietary lutein as well as 1 and 3 are accumulated in the human macula and have been implicated in the prevention of age-related macular degeneration. (3R)-β-Cryptoxanthin (4) is also present in selected ocular tissues at a very low concentration whereas its enantiomer (3S)-β-cryptoxanthin (5) is absent in foods and human plasma.

The present invention relates to a process for the synthesis of (3R)-3-hydroxy-β-ionone and its (3S)-enantiomer in high optical purity from commercially available (rac)-α-ionone. The key intermediate for the synthesis of these hydroxyionones is 3-keto-α-ionone ketal that was prepared from (rac)-α-ionone after protection of this ketone as a 1,3-dioxolane. Reduction of 3-keto-α-ionone ketal followed by deprotection, lead to 3-hydroxy-α-ionone that was transformed into (rac)-3-hydroxy-β-ionone by base-catalyzed double bond isomerization in 46% overall yield from (rac)-α-ionone. The racemic mixture of these hydroxyionones was then resolved by enzyme-mediated acylation in 96% ee. (3R)-3-Hydroxy-β-ionone and its (3S)-enantiomer were respectively transformed to (3R)-3-hydroxy-(β-ionylideneethyl)triphenylphosphonium chloride [(3R)—C₁₅-Wittig salt] and its (3S)-enantiomer [(3S)—C₁₅-Wittig salt] according to known procedures. Double Wittig condensation of these Wittig salts with commercially available 2,5-dimethylocta-2,4,6-triene-1,8-dial provided all 3 stereoisomers of zeaxanthin (1-3). Similarly, (3R)—C₁₅-Wittig and its (3S)-enantiomer were each coupled with β-apo-12′-carotenal to yield 4 and 5.

A recombinant microbial host cell is provided capable of producing astaxanthin from β-carotene without a measurable concomitant accumulation of ketolated or hydroxylated intermediates such as adonixanthin, zeaxanthin, adonirubin, echinenone, 3-hydroxyechinenone, 3′-hydroxyechinenone, canthaxanthin, and β-cryptoxanthin. Specifically, a β-carotene producing microbial host cell was engineered to express two heterologous genes, a β-carotene ketolase from Chlamydomonas reinhardtii in combination with a carotenoid hydroxylase from Brevundimonas vesicularis or Arabidopsis thaliana.

[Object] To provide a canthaxanthin selective producing bacterium being able to easily extract and purify canthaxanthin, which is one of carotenoids, and a method for producing canthaxanthin by a culture method.

[Solving Means] A carotenoid producing bacterium belonging to the genus Paracoccus is provided which selectively produces canthaxanthin so that the amount thereof is not less than 90 percent by weight of the total amount of produced carotenoids including β-carotene, β-cryptoxanthin, echinenone, canthaxanthin, 3-hydroxyechinenone, 3′-hydroxyechinenone, zeaxanthin, phoenicoxanthin, adonixanthin, and astaxanthin. In addition, a method for producing canthaxanthin is provided which has the steps of culturing the above bacterium, and then collecting carotenoids from bacterial cells or a culture solution after the culturing.

The present invention relates to the isolation of carotenoids and in particular the xanthophyll zeaxanthin (zeaxanthin-β,β-Carotene-3,3′-diol) and optionally other carotenoids such as lycopene, β,β-carotene, 3′-hydroxyechinenone β-cryptoxanthin and the colourless carotenoids, phytoene and phytofluene from a marine bacterium belonging to the genus Algibacter which is capable of producing the aforementioned compounds. The present invention also provides a strain of Algibacter which is capable of producing significant levels of carotenoids, especially zeaxanthin at high purity, as well as methods of using the Algibacter strain and uses of the carotenoids produced.

The invention discloses an anti-free-radical composition and a preparation method and application thereof, and belongs to the field of cigarette additives and application thereof. The composition is prepared from the following raw materials in parts by weight: 3 to 10 parts of cryptoxanthin, 4.5 to 20 parts of curcumin, 0.2 to 2 parts of an antioxidant, 0.4 to 1.2 parts of an excipient, 8 to 15 parts of vegetable oil and 72 to 89 parts of a water-soluble polymer. The method comprises the following steps: 1) mixing the cryptoxanthin, the curcumin, the antioxidant, the excipient, the vegetable oil and the water-soluble polymer in parts by weight to obtain a mixture; and (2) adding the mixture into a double-screw extruder, and performing extruding to obtain a powder, namely the anti-free-radical composition. The invention discloses the application of the anti-free-radical composition in the field of preparation of electronic cigarette additives, and the anti-free-radical composition has agood effect of scavenging free radicals, and is easy to atomize, stable in character and free from toxic or side effect.

Mushrooms genetically engineered to produce provitamin A carotenoids including α-carotene, β-carotene, γ-carotene, and β-cryptoxanthin are provided. In some embodiments, mushrooms are transformed with genes that encode enzymes that have phytoene synthase, pyhtoene dehydrogenase and lycopene cyclase activities and function to convert GGPP to one or more provitamin A carotenoids. Mushrooms are transformed using known methods, including Agrobacterium-mediated transformation. Transgenic mushrooms producing provitamin A carotenoids are useful to treat, alleviate, reduce, and/or inhibit one or more symptoms of a disease or disorder associated with vitamin A deficiency (VAD).